Obaseiki-Ebor E E
Department of Pharmaceutical Microbiology, Faculty of Pharmacy, University of Benin, Nigeria.
Afr J Med Med Sci. 1988 Sep;17(3):175-9.
The susceptibility of 40 Escherichia coli and 35 Klebsiella spp. urinary isolates to trimethoprim/sulphamethoxazole (cotrimoxazole) was determined. The determination was based on the activity of the standard multodiscs-cotrimoxazole (25 micrograms), (Oxoid); sulphafurazole (500 micrograms), (Mastring-S); and the minimum inhibitory concentration of trimethoprim and sulphamethoxazole singly against the isolates. Thirty-two (80%) of 40 isolates of Escherichia coli, and 26 (74%) of 35 isolates of Klebsiella spp. were resistant to cotrimoxazole. All the isolates were resistant to more than 500 mg/l sulphamethoxazole. Twenty of the 32 (62%) cotrimoxazole-resistant E. coli strains and 18 of the 26 (69%) cotrimoxazole-resistant Klebsiella strains were resistant to more than 2000 mg/l trimethoprim. These high level trimethoprim-resistant strains invariably carried transferable resistance to at least the sulphonamides, ampicillin and tetracycline, which could be transferred en bloc to known sensitive recipients by the process of conjugation. The high incidence of the R-plasmid-mediated resistance to high levels of trimethoprim suggests the presence of a selective pressure from the increased, and probably the uncontrolled, use of trimethoprim/sulphonamide proprietary formulations in the society.
测定了40株大肠埃希菌和35株克雷伯菌属尿液分离株对甲氧苄啶/磺胺甲恶唑(复方新诺明)的敏感性。该测定基于标准多盘 - 复方新诺明(25微克)(Oxoid公司)、磺胺异恶唑(500微克)(Mastring - S)的活性以及甲氧苄啶和磺胺甲恶唑单独对分离株的最低抑菌浓度。40株大肠埃希菌分离株中有32株(80%),35株克雷伯菌属分离株中有26株(74%)对复方新诺明耐药。所有分离株对超过500mg/l的磺胺甲恶唑耐药。32株对复方新诺明耐药的大肠埃希菌菌株中有20株(62%),26株对复方新诺明耐药的克雷伯菌菌株中有18株(69%)对超过2000mg/l的甲氧苄啶耐药。这些高水平耐甲氧苄啶菌株总是携带至少对磺胺类、氨苄西林和四环素的可转移耐药性,可通过接合过程整体转移给已知的敏感受体。R质粒介导的对高水平甲氧苄啶耐药的高发生率表明社会中存在因甲氧苄啶/磺胺类专有制剂使用增加且可能不受控制而产生的选择压力。